Low expression of CD39 on regulatory T cells as a biomarker for resistance to methotrexate therapy in rheumatoid arthritis

Proceedings of the National Academy of Sciences of the United States of America

Volumn 112, Issue 8, 2015, Pages 2509-2514

  Peres, Raphael Sanches ^a   Liew, Foo Y ^b,c   Talbot, Jhimmy ^a   Carregaro, Vanessa ^a   Oliveira, Rene D ^d   Almeida, Sergio L ^d   França, Rafael F O ^a   Donate, Paula B ^a   Pinto, Larissa G ^a   Ferreira, Flavia I S ^d   Costa, Diego L ^a   Demarque, Daniel P ^d   Gouvea, Dayana Rubio ^d   Lopes, Norberto P ^d   Queiroz, Regina Helena C ^d   Silva, Joao Santana ^a   Figueiredo, Florencio ^e   Alves Filho, Jose Carlos ^a   Cunhaa, Thiago M ^a   Ferreir, Sérgio H ^a   Louzada Junior, Paulo ^d   Cunha, Fernando Q ^a   more..

^a Department of Pharmacology ^*  (Brazil)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c SOOCHOW UNIVERSITY   (China)

^d UNIVERSITY OF SÃO PAULO   (Brazil)

^e UNIVERSITY OF BRASILIA   (Brazil)

Author keywords

Adenosine; Biomarker; Ectonucleotidases; Methotrexate; Rheumatoid arthritis

Indexed keywords

5' NUCLEOTIDASE; ADENOSINE; ADENOSINE TRIPHOSPHATE; CD39 ANTIGEN; INTERLEUKIN 1BETA; METHOTREXATE; NUCLEOTIDASE; TRANSCRIPTION FACTOR FOXP3; TUMOR NECROSIS FACTOR ALPHA; APYRASE; BIOLOGICAL MARKER; LEUKOCYTE ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; CD4+ CD25+ T LYMPHOCYTE; CELL DENSITY; CELL SURFACE; CONTROLLED STUDY; DEGRADATION; HUMAN; HUMAN CELL; IMMUNOREGULATION; MAJOR CLINICAL STUDY; MONOTHERAPY; MOUSE; NONHUMAN; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; PROSPECTIVE STUDY; REGULATORY T LYMPHOCYTE; RHEUMATOID ARTHRITIS; TH1 CELL; TH17 CELL; TREATMENT DURATION; TREATMENT RESPONSE; ANIMAL; ARTHRITIS, EXPERIMENTAL; ARTHRITIS, RHEUMATOID; C57BL MOUSE; DRUG EFFECTS; DRUG RESISTANCE; IMMUNOLOGY; LYMPHOCYTE COUNT; METABOLISM; PATHOLOGY;

MURINAE;

5'-NUCLEOTIDASE; ADENOSINE; ANIMALS; ANTIGENS, CD; APYRASE; ARTHRITIS, EXPERIMENTAL; ARTHRITIS, RHEUMATOID; BIOMARKERS; DRUG RESISTANCE; HUMANS; LYMPHOCYTE COUNT; METHOTREXATE; MICE, INBRED C57BL; T-LYMPHOCYTES, REGULATORY; TH1 CELLS; TH17 CELLS;

EID: 84923675354     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1424792112     Document Type: Article

References (34)

1. McInnes IB, Schett G (2011) The pathogenesis of rheumatoid arthritis. N Engl J Med 365(23):2205-2219.
2. Aletaha D, et al. (2010) 2010 rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 69(9):1580-1588.
3. Emery P, Dörner T (2011) Optimising treatment in rheumatoid arthritis: A review of potential biological markers of response. Ann Rheum Dis 70(12):2063-2070.
4. Cronstein BN (2005) Low-dose methotrexate: A mainstay in the treatment of rheumatoid arthritis. Pharmacol Rev 57(2):163-172.
5. Bansard C, et al. (2009) Can rheumatoid arthritis responsiveness to methotrexate and biologics be predicted? Rheumatology (Oxford) 48(9):1021-1028.
6. Cronstein BN, Eberle MA, Gruber HE, Levin RI (1991) Methotrexate inhibits neutrophil function by stimulating adenosine release from connective tissue cells. Proc Natl Acad Sci USA 88(6):2441-2445.
7. Deaglio S, et al. (2007) Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J Exp Med 204(6):1257-1265.
8. Montesinos MC, et al. (2000) Reversal of the antiinflammatory effects of methotrexate by the nonselective adenosine receptor antagonists theophylline and caffeine: Evidence that the antiinflammatory effects of methotrexate are mediated via multiple adenosine receptors in rat adjuvant arthritis. Arthritis Rheum 43(3):656-663.
9. Nesher G, Mates M, Zevin S (2003) Effect of caffeine consumption on efficacy of methotrexate in rheumatoid arthritis. Arthritis Rheum 48(2):571-572.
10. Montesinos MC, et al. (2007) The antiinflammatory mechanism of methotrexate depends on extracellular conversion of adenine nucleotides to adenosine by ecto-5?-nucleotidase: findings in a study of ecto-5?-nucleotidase gene-deficient mice. Arthritis Rheum 56(5):1440-1445.
11. Fontenot JD, Gavin MA, Rudensky AY (2003) Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol 4(4):330-336.
12. Hori S, Nomura T, Sakaguchi S (2003) Control of regulatory T cell development by the transcription factor Foxp3. Science 299(5609):1057-1061.
13. Khattri R, Cox T, Yasayko SA, Ramsdell F (2003) An essential role for Scurfin in CD4+ CD25+ T regulatory cells. Nat Immunol 4(4):337-342.
14. Sakaguchi S, Yamaguchi T, Nomura T, Ono M (2008) Regulatory T cells and immune tolerance. Cell 133(5):775-787.
15. Sitkovsky MV, Ohta A (2005) The 'danger' sensors that STOP the immune response: The A2 adenosine receptors? Trends Immunol 26(6):299-304.
16. Haskó G, Linden J, Cronstein B, Pacher P (2008) Adenosine receptors: therapeutic aspects for inflammatory and immune diseases. Nat Rev Drug Discov 7(9):759-770.
17. Haskó G, Cronstein BN (2004) Adenosine: An endogenous regulator of innate immunity. Trends Immunol 25(1):33-39.
18. Zarek PE, et al. (2008) A2A receptor signaling promotes peripheral tolerance by inducing T-cell anergy and the generation of adaptive regulatory T cells. Blood 111(1): 251-259.
19. Carregaro V, et al. (2011) Nucleosides from Phlebotomus papatasi salivary gland ameliorate murine collagen-induced arthritis by impairing dendritic cell functions. J Immunol 187(8):4347-4359.
20. Li L, et al. (2012) Dendritic cells tolerized with adenosine A2AR agonist attenuate acute kidney injury. J Clin Invest 122(11):3931-3942.
21. Palmer TM, Trevethick MA (2008) Suppression of inflammatory and immune responses by the A(2A) adenosine receptor: An introduction. Br J Pharmacol 153(Suppl 1):S27-S34.
22. Dervieux T, Greenstein N, Kremer J (2006) Pharmacogenomic and metabolic biomarkers in the folate pathway and their association with methotrexate effects during dosage escalation in rheumatoid arthritis. Arthritis Rheum 54(10):3095-3103.
23. Dalrymple JM, et al. (2008) Pharmacokinetics of oral methotrexate in patients with rheumatoid arthritis. Arthritis Rheum 58(11):3299-3308.
24. Cronstein BN, Merrill JT (1996) Mechanisms of the effects of methotrexate. Bull Rheum Dis 45(5):6-8.
25. Genestier L, et al. (1998) Immunosuppressive properties of methotrexate: Apoptosis and clonal deletion of activated peripheral T cells. J Clin Invest 102(2):322-328.
26. Reutershan J, et al. (2009) Adenosine and inflammation: CD39 and CD73 are critical mediators in LPS-induced PMN trafficking into the lungs. FASEB J 23(2):473-482.
27. Urano W, et al. (2002) Polymorphisms in the methylenetetrahydrofolate reductase gene were associated with both the efficacy and the toxicity of methotrexate used for the treatment of rheumatoid arthritis, as evidenced by single locus and haplotype analyses. Pharmacogenetics 12(3):183-190.
28. Wessels JA, et al. (2006) Efficacy and toxicity of methotrexate in early rheumatoid arthritis are associated with single-nucleotide polymorphisms in genes coding for folate pathway enzymes. Arthritis Rheum 54(4):1087-1095.
29. Owen SA, et al. (2013) MTHFR gene polymorphisms and outcome of methotrexate treatment in patients with rheumatoid arthritis: Analysis of key polymorphisms and meta-analysis of C677T and A1298C polymorphisms. Pharmacogenomics J 13(2): 137-147.
30. Owen SA, et al. (2013) Genetic polymorphisms in key methotrexate pathway genes are associated with response to treatment in rheumatoid arthritis patients. Pharmacogenomics J 13(3):227-234.
31. Plant D, Wilson AG, Barton A (2014) Genetic and epigenetic predictors of responsiveness to treatment in RA. Nat Rev Rheumatol 10(6):329-337.
32. Enjyoji K, et al. (2008) Deletion of cd39/entpd1 results in hepatic insulin resistance. Diabetes 57(9):2311-2320.
33. Friedman DJ, et al. (2009) Functional ENTPD1 polymorphisms in African Americans with diabetes and end-stage renal disease. Diabetes 58(4):999-1006.
34. Liao H, Hyman MC, Baek AE, Fukase K, Pinsky DJ (2010) cAMP/CREB-mediated transcriptional regulation of ectonucleoside triphosphate diphosphohydrolase 1 (CD39) expression. J Biol Chem 285(19):14791-14805.